MGI Pharma MOGN New patents, anti cancer Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGI Pharma MOGN New patents, anti cancer

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: seminole who wrote (636)	2/6/1998 9:13:00 AM
From: Biomaven	Read Replies (2) of 1826

Richard - I'm confused with the info in the reference you cited. Compare >> Further dose escalation is ongoing at 6.0 mg/m2/day, with an estimated MTD of 8.04 mg/m2/day according to the mCRM.>> with an earlier post by David Cathcart on this thread: >> > Do you know which dose MOGN is now administrating, and are there any evidence of the side effects?< The current MGI 114 dose rate is 14 mg/m^2. The next dose rate of 19 mg/m^2 is expected to occur this month. All signs of toxicity thus far have been considered minor and easily manageable. Dose limiting toxicity is now expected to occur at 20 mg/m^2 or higher.>> Maybe your reference related to earlier in the study? There is also a discrepancy with the toxic dose in dogs. Compare Joseph von Meister's post: >>I specualte that the reason for this was that 114, when tested on dogs, caused toxicity at 8-9 mg/m^2>> with your reference: >>Dose-limiting toxicities have not occurred despite doses of MGI 114 exceeding 3 mg/m2/day which induced severe myelosuppression in dogs.>> I wonder if the confusion stems from the mg/m^2 vs. mg/kg dosage conversion? Peter

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next